Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 137.50
Bid: 135.00
Ask: 140.00
Change: -2.50 (-1.79%)
Spread: 5.00 (3.704%)
Open: 140.00
High: 137.50
Low: 133.00
Prev. Close: 140.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Price Monitoring Extension

8 May 2018 09:00

RNS Number : 3401N
Faron Pharmaceuticals Oy
08 May 2018
 

Price Monitoring Extension

The auction call period has been extended in this security by 5 minutes.

Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before the execution occurs. A price monitoring extension is activated when the matching process would have otherwise resulted in an execution price that is a pre-determined percentage above or below the price of the most recent automated execution today.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PMEFKFDKFBKKKPK
Date   Source Headline
28th Mar 20247:00 amRNSIssue of Warrants to IPF Funding Update
26th Mar 202410:00 amRNSFaron´s Annual Report 2023
18th Mar 20247:00 amRNSAdditional Positive Data from Phase 1 of BEXMAB
14th Mar 20247:00 amRNSFaron to Host BEXMAB Webcast
13th Mar 20242:00 pmRNSNotice of Annual General Meeting 2024
13th Mar 20247:00 amRNSFinancial Statement January 1 to December 31 2023
4th Mar 20247:00 amRNSBinding commitments for convertible loans
28th Feb 20244:00 pmRNSReplacement - Update to 2024 Financial Calendar
27th Feb 20246:00 pmRNSUpdate to Faron’s Financial Calendar for 2024
21st Feb 20242:00 pmRNSContinued Negotiations Regarding Events of Default
19th Feb 202410:30 amRNSEvents of Default
31st Jan 20247:00 amRNSFurther re: Exercise of options
25th Jan 20247:00 amRNSBEXMAB Insights into Patient Profiles
19th Jan 20241:00 pmRNSExercise of options - Issue of equity
9th Jan 20247:00 amRNSFirst Patient Dosed in Ph 2 of the BEXMAB Trial
3rd Jan 20247:00 amRNSPresentation at J.P. Morgan Healthcare Conference
22nd Dec 20237:00 amRNSFaron’s Financial Calendar for 2024
11th Dec 20237:00 amRNSPhase 1 BEXMAB data presented at ASH
7th Dec 20237:00 amRNSMATINS Trial in Cell Reports Medicine
4th Dec 20237:00 amRNSGrant of options
6th Nov 20238:13 amRNSFaron Initiates Phase 2 Part of BEXMAB Study
6th Nov 20237:00 amRNSFaron Initiates Phase 2 Part of BEXMAB Study
2nd Nov 20231:00 pmRNSFaron to present data from BEXMAB study at ASH
27th Oct 20231:00 pmRNSManager's transactions
27th Oct 20237:15 amRNSExercise of options
27th Oct 20237:00 amRNSResults of Placing
26th Oct 20234:30 pmRNSProposed Issue and Placing
11th Oct 20237:00 amRNSFaron Announces Positive BEXMAB Study Update
3rd Oct 20237:00 amRNSFaron to host webcast on new BEXMAB study data
22nd Sep 20234:00 pmRNSBoard Changes
22nd Sep 202311:00 amRNSResults of EGM
21st Sep 20237:00 amRNSFaron Appoints Interim Chief Medical Officer
8th Sep 20237:00 amRNSChange in the Board of Directors
6th Sep 20237:00 amRNSFaron to Present at H.C. Wainwright Conference
1st Sep 202310:00 amRNSNotice of EGM
31st Aug 20232:00 pmRNSExercise of options
29th Aug 20237:01 amRNSFaron 2023 Half-Year Financial Results
29th Aug 20237:00 amRNSFDA Orphan Drug Designation for Bexmarilimab
4th Aug 20237:00 amRNSNotice of Half-Year Financial Results
2nd Aug 20237:00 amRNSFaron to Participate at Canaccord Conference
25th Jul 20237:00 amRNSGrant of Options
19th Jul 20237:01 amRNSFaron to Hold BEXMAB Study Conference Call
19th Jul 20237:00 amRNSBEXMAB study update
30th Jun 20234:52 pmRNSHolding(s) in Company
29th Jun 20237:00 amRNSAnnouncement of Placing
12th Jun 20237:00 amRNSExercise of options
9th Jun 20238:00 amRNSNew biomarker data from BEXMAB study at EHA2023
5th Jun 20237:00 amRNSBoard Member to Assume Transactional Advisor Role
24th Apr 20237:00 amRNSBexmarilimab Efficacy and Safety in MATINS Trial
19th Apr 20237:00 amRNSBexmarilimab KOL Event

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.